AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02846532
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
Trial: NCT03179917
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.
Trial: NCT00723359
Drug: BT062
RxNorm normalized name: Brentuximab vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: biologic
Trial: NCT04069429
Drug: Technetium Tc 99M
RxNorm normalized name: TECHNETIUM Tc 99m
DrugBank: Technetium Tc-99m (DB14227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects are administered radioactive heparin as part of study participation.
Trial: NCT00920699
Drug: CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Trial: NCT00212797
Drug: Org 34517
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose Org 34517
Trial: NCT00862433
Drug: Alpha tocopherol
RxNorm normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
Trial: NCT00212797
Drug: Org 34517
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose Org 34517
Trial: NCT02498392
Drug: JNJ-42165279
RxNorm normalized name: JNJ-42165279
DrugBank: JNJ-42165279 (DB15173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
Trial: NCT03023852
Drug: JNJ-63623872
RxNorm normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
Trial: NCT03023852
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
Trial: NCT01281917
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
Trial: NCT01281917
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
Trial: NCT02473289
Drug: Sirukumab 50 mg
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
Trial: NCT00544115
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544115
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00544115
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544115
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00544115
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00544115
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544115
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00544115
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04557059
Drug: LHRHa
RxNorm normalized name: ALARELIN ACETATE 800 ug in 1 mg INTRAMUSCULAR INJECTION, POWDER, FOR SUSPENSION [LHRHa]
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
Trial: NCT04557059
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
Trial: NCT02523014
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04723732
Drug: Myrrh mouthwash
RxNorm normalized name: Myrrh
DrugBank: Myrrh (DB11605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
Trial: NCT04723732
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% mouthwash solution of chlorhexidine gluconate.
Trial: NCT02523014
Drug: FAK Inhibitor GSK2256098
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: GSK2256098 (DB16106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02957162
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02523014
Drug: Capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02523014
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03466411
Drug: Guselkumab Dose 1
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered by IV infusion.
Trial: NCT03466411
Drug: Guselkumab Dose 2
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered by SC injection.
Trial: NCT03466411
Drug: Guselkumab Dose 3
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered by IV infusion.
Trial: NCT03466411
Drug: Guselkumab Dose 4
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered by IV infusion.
Trial: NCT03466411
Drug: Guselkumab Dose 5
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be by SC injection.
Trial: NCT04009499
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive bimekizumab at pre-specified time-points.
Trial: NCT03466411
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered by IV infusion and SC injection.
Trial: NCT03466411
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab will be administered by IV infusion and SC injection.
Trial: NCT02996097
Drug: Intralesional Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02960126
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02960126
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01978236
Drug: Dabrafenib 150 mg
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
Trial: NCT01978236
Drug: Trametinib 2.0 mg
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
Trial: NCT04232878
Drug: CVL-936
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL-936
Trial: NCT02831998
Drug: ChloraPrep
RxNorm normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT02831998
Drug: ZP Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT03811834
Drug: Mobocertinib
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
Trial: NCT00576823
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 0.2 mg/kg/day~Route: oral
Trial: NCT03638258
Drug: Roflumilast Cream 0.3%
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied once daily for 12 weeks
Trial: NCT03638258
Drug: Roflumilast Cream 0.15%
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied once daily for 12 weeks
Trial: NCT03134547
Drug: low dose sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low volume volatile anesthetics (1.0%)
Trial: NCT03134547
Drug: high dose sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high volume volatile anesthetics (2.5%)
Trial: NCT01678898
Drug: PRX-102
RxNorm normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03150693
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03150693
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, SC
Trial: NCT03150693
Drug: Daunorubicin Hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03150693
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03150693
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT03150693
Drug: Pegylated L-Asparaginase
RxNorm normalized name: Pegylated dickeya chrysanthemi l-asparaginase
DrugBank: Pegcrisantaspase (DB16281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03150693
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01249352
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, IV Weekly IV dose for up to 26 weeks.
Trial: NCT01249352
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
Trial: NCT00437619
Drug: calcipotriol hydrate [Daivonex]
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
Trial: NCT00640042
Drug: morphine sulfate extended release capsules
RxNorm normalized name: morphine sulfate Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
Trial: NCT02852395
Drug: JNJ-48816274
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose; dose range of 5 mg up to 250 mg
Trial: NCT01934660
Drug: Fludeoxyglucose F18
RxNorm normalized name: fludeoxyglucose F18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01934660
Drug: 13N-amonia
RxNorm normalized name: ammonia (13N)
DrugBank: Ammonia (DB11118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02486718
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Trial: NCT02486718
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Trial: NCT02486718
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Trial: NCT02486718
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Trial: NCT02486718
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Trial: NCT02486718
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Trial: NCT02261285
Drug: ONO-4538
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01560585
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
Trial: NCT01020747
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
Trial: NCT03592823
Drug: Hydroxychloroquine Sulfate 200 Mg Tablet
RxNorm normalized name: hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg, bidpo.
Trial: NCT03028012
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Trial: NCT03028012
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Trial: NCT01726517
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT04119050
Drug: M281
RxNorm normalized name: Immunoglobulin g1, anti-(human neonatal fc receptor) (human monoclonal m281 .gamma.-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M281 injection administered as intravenous infusion
Trial: NCT00148135
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00148135
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03523442
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participants will receive apalutamide 240 mg once daily orally.
Trial: NCT04385433
Drug: EXPERIMENTAL ARM
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).
Trial: NCT03705533
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
Trial: NCT03705533
Drug: Micardis
RxNorm normalized name: Micardis
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Trial: NCT01363297
Drug: Inotuzumab Ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2.
Trial: NCT04206488
Drug: JNJ-70033093
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-70033093 orally.
Trial: NCT04206488
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive digoxin orally.
Trial: NCT01993576
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
Trial: NCT03990519
Drug: JNJ-26366821
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
Trial: NCT03451851
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.
Trial: NCT03451851
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
Trial: NCT03451851
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
Trial: NCT00702273
Drug: 150 µg Corifollitropin Alfa
RxNorm normalized name: peginterferon alfa-2b
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.